Areteia Therapeutics
Business Services · North Carolina, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
101 Glen Lennox Dr Unit 300, Chapel Hill...Website
www.areteiatx.comRevenue
$14.7 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Areteia Therapeutics
Areteia Therapeutics is a clinical stage biotechnology company whose purpose is to develop and deliver novel Inflammation and Immunology therapies.Explore more
Areteia Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Areteia Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Areteia Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Areteia Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Areteia Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Areteia Therapeutics
Check out if Areteia Therapeutics is spiking on competitors!
Product Launch: Get notified when Areteia Therapeutics launches new products
Funding: Get notified immidiatlly once Areteia Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Areteia Therapeutics had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Areteia Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Areteia Therapeutics
Compare insights from companies similar to Areteia Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Areteia Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Areteia Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Areteia Therapeutics.
Areteia Therapeutics financials insights
Gather financial insights about Areteia Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$75M
Areteia Therapeutics Tech Stack
A closer look at the technologies used by Areteia Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Person-Based
Person-Based
Executive Move
Board of Directors
Funding
Funding
Areteia Therapeutics News & Media
Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Areteia Therapeutics, Inc. (“Areteia”), a clinical-stage biotechnology company developing novel inflammation and immunology therapies, with an initial focus on severe eosinophilic asthma, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025 at 1:30 p.m. PT in San Francisco, CA. A copy of the presentation will be posted on the Company’s website following the presentation. Event: J.P. MAreteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately. Dr. Becker will serve as a member of the audit committee of the board. “I am excited that Dan has been appointed to our board,” said Jorge Bartolome, President and Chief Executive Officer of Areteia. “He is an incredibly accomplished executive whose depth of biotech experience, proven leadership and scientific experAreteia Therapeutics Announces Additional $75MM in Series A Financing for Oral Dexpramipexole in Eosinophilic Asthma
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Areteia Therapeutics, Inc. (“Areteia”) today announced $75 million in additional Series A financing to support expansion of the current Phase III development program of dexpramipexole in eosinophilic asthma, bringing total Series A funding to $425 million. Viking Global Investors and Marshall Wace join the original syndicate of investors led by Bain Capital Life Sciences with participation from Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners,Areteia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Areteia Therapeutics, Inc. (“Areteia”) announced today that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 9, 2024 at 1:30 p.m. PT in San Francisco, CA. Areteia (areteiatx.com) is a clinical stage biotechnology company whose purpose is to develop and deliver novel Inflammation and Immunology (I&I) therapies that put respiratory patients in better control of their disease and back in control of their lives. De
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Areteia Therapeutics
Sign Up For FreeTo access detailed company insights
Areteia Therapeutics is a clinical stage biotechnology company whose purpose is to develop and deliver novel Inflammation and Immunology therapies.... Read More
